AstraZeneca surges to new 52-week high on better than expected Q1
First quarter sales and profit beat expectationsStrategy update scheduled for 21 MayFull year outlook confirmedShares in AstraZeneca (AZN) surged 5% to £119.3 closing in on a new 52-week high after first quarter revenue and earnings eclipsed market expectations and the pharmaceutical company reiterated full year guidance.After a few months of consolidation, the shares are back to winning ways and